General
Preferred name
PRIMIDONE
Synonyms
Primidonum ()
Primaclone ()
Mysoline ()
NCI-C56360 ()
Liskantin ()
NSC-41701 ()
Lepimidin ()
Lepsiral ()
Primidona ()
Resimatil ()
Primidone (CRM) ()
P&D ID
PD001787
CAS
125-33-7
Tags
available
drug
Approved by
FDA
First approval
1954
Drug indication
Epilepsy
Drug Status
vet_approved
approved
Max Phase
4.0
Probe control
Probe control not defined
Orthogonal probes
0
No orthogonal probes found
Similar probes
0
No structurally similar probes found
Structure
P&D probe-likeness score
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION
Primidone is a barbiturate anticonvulsant. Clinical use of primidone has largely been replaced by newer alternatives.
(GtoPdb)
DESCRIPTION
Primidone is the orally active inhibitor for TRPM3 (IC50 = 0.6 ¦ÌM), RIP kinase and voltage-gated sodium channel, and the antagonist for GABA receptor. Primidone can be used as the analgesic and anticonvulsant agent[1][2][3].
PRICE
29
DESCRIPTION
Anticonvulsant
(LOPAC library)
DESCRIPTION
Potentiates GABAA receptor function
(Tocriscreen Total)
DESCRIPTION
Primidone is an anticonvulsant of the pyrimidinedione class that can be detected in urine. It is presumed to be a modulator of GABAA receptors. Primidone is commonly indicated for the management of grand mal, psychomotor, and focal epileptic seizures.
(Enamine Bioactive Compounds)
DESCRIPTION
Primidone (NCI-C56360) is a potent anticonvulsant agent. It is a neuronal voltage-gated sodium channel blocker and has value in the study of epilepsy, essential tremor, and psychiatric disorders.
(TargetMol Bioactive Compound Library)
[[ p.pathway_name ]]
[[ compound.targets[tid].gene_name ]]
Compound Sets
32
CeMM library of unique drugs (CLOUD)
ChEMBL Approved Drugs
ChEMBL Drugs
Concise Guide to Pharmacology 2019/20
Concise Guide to Pharmacology 2021/22
Concise Guide to Pharmacology 2023/24
CZ-OPENSCREEN Bioactive Library
Drug Repurposing Hub
DrugBank
DrugBank Approved Drugs
DrugCentral
DrugCentral Approved Drugs
DrugMAP
DrugMAP Approved Drugs
DrugMatrix
Enamine Bioactive Compounds
Enamine BioReference Compounds
EU-OPENSCREEN Bioactive Compound Library
Guide to Pharmacology
LOPAC library
LSP-MoA library (Laboratory of Systems Pharmacology)
MedChem Express Bioactive Compound Library
NCATS Inxight Approved Drugs
NIH Clinical Collections (NCC)
NPC Screening Collection
Prestwick Chemical Library
ReFrame library
Selleckchem Bioactive Compound Library
TargetMol Bioactive Compound Library
The Spectrum Collection
Tocriscreen Total
[[ a.name ]]
[[ ligand_id ]]
free of charge
External IDs
39
Molecular Weight
218.11
Hydrogen Bond Acceptors
2
Hydrogen Bond Donors
2
Rotatable Bonds
2
Ring Count
2
Aromatic Ring Count
1
cLogP
0.54
TPSA
58.2
Fraction CSP3
0.33
Chiral centers
0.0
Largest ring
6.0
QED
0.71
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
MOA
ionotropic GABA receptor agonist
GABA Receptor antagonist
Target
Sodium channel alpha subunit
GABA-A receptor
anion channel
GABAR
GluR2
nAChR
Sodium Channel
CHRNA4, CHRNA7, GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ, GRIA2, GRIK2, SCN10A, SCN11A, SCN1A, SCN2A, SCN3A, SCN4A, SCN5A, SCN7A, SCN8A, SCN9A
GABA Receptor
Necroptosis
RIP Kinase
TRP Channel
Indication
seizures
Pathway
Membrane Transporter/Ion Channel
Neuroscience
Apoptosis
Neuronal Signaling
Therapeutic Class
Anticonvulsants
Source data
